Advanced SearchSearch Tips
Four-Week Repeated Intravenous Dose Toxicity and Toxicokinetic Study of TS-DP2, a Novel Human Granulocyte Colony Stimulating Factor in Rats
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : Toxicological Research
  • Volume 31, Issue 4,  2015, pp.371-392
  • Publisher : The Korean Society of Toxicology
  • DOI : 10.5487/TR.2015.31.4.371
 Title & Authors
Four-Week Repeated Intravenous Dose Toxicity and Toxicokinetic Study of TS-DP2, a Novel Human Granulocyte Colony Stimulating Factor in Rats
Lee, JooBuom; Lee, Kyungsun; Choe, Keunbum; Jung, Hyunseob; Cho, Hyunseok; Choi, Kiseok; Kim, Taegon; Kim, Seojin; Lee, Hyeong-Seok; Cha, Mi-Jin; Song, Si-Whan; Lee, Chul Kyu; Chun, Gie-Taek;
  PDF(new window)
TS-DP2 is a recombinant human granulocyte colony stimulating factor (rhG-CSF) manufactured by TS Corporation. We conducted a four-week study of TS-DP2 (test article) in repeated intravenous doses in male and female Sprague-Dawley (SD) rats. Lenograstim was used as a reference article and was administered intravenously at a dose of . Rats received TS-DP2 intravenously at doses of 250, 500, and once daily for 4 weeks, and evaluated following a 2-week recovery period. Edema in the hind limbs and loss of mean body weight and body weight gain were observed in both the highest dose group of TS-DP2 and the lenograstim group in male rats. Fibro-osseous lesions were observed in the lenograstim group in both sexes, and at all groups of TS-DP2 in males, and at doses of TS-DP2 and higher in females. The lesion was considered a toxicological change. Therefore, bone is the primary toxicological target of TS-DP2. The lowest observed adverse effect level (LOAEL) in males was , and no observed adverse effect level (NOAEL) in females was in this study. In the toxicokinetic study, the serum concentrations of G-CSF were maintained until 8 hr after administration. The systemic exposures ( and ) were not markedly different between male and female rats, between the administration periods, or between TS-DP2 and lenograstim. In conclusion, TS-DP2 shows toxicological similarity to lenograstim over 4-weeks of repeated doses in rats.
 Cited by
Glaspy, J.A. (2003) Hematopoietic management in oncology practice. Part 1. Myeloid growth factors. Oncology, 17, 1593-1603.

El Ouriaghli, F., Fujiwara, H., Melenhorst, J.J., Sconocchia, G., Hensel, N. and Barrett, A.J. (2003) Neutrophil elastase enzymatically antagonizes the in vitro action of G-CSF: implications for the regulation of granulopoiesis. Blood, 101, 1752-1758. crossref(new window)

Yong, K.L. (1996) Granulocyte colony-stimulating factor (GCSF) increases neutrophil migration across vascular endothelium independent of an effect on adhesion: Comparison with granulocyte-macrophage colony-stimulating factor (GMCSF). Br. J. Haematol., 94, 40-47. crossref(new window)

Morstyn, G., Campbell, L., Souza, L.M., Alton, N.K., Keech, J., Green, M., Sheridan, W., Metcalf, D. and Fox, R. (1988) Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet, 1, 667-672.

Price, T.H., Chatta, G.S. and Dale, D.C. (1996) Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood, 88, 335-340.

Glaspy, J.A., Baldwin, G.C., Robertson, P.A., Souza, L., Vincent, M., Ambersley, J. and Golde, D.W. (1988) Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann. Intern. Med., 109, 789-795. crossref(new window)

Yokose, N., Ogata, K., Tamura, H., An, E., Nakamura, K., Kamikubo, K., Kudoh, S., Dan, K. and Nomura, T. (1998) Pulmonary toxicity after granulocyte colonystimulating factor- combined chemotherapy for non-Hodgkin's lymphoma. Br. J. Cancer, 77, 2286-2290. crossref(new window)

Johnston, E., Crawford, J., Blackwell, S., Bjurstrom, T., Lockbaum, P., Roskos, L., Yang, B.B., Gardner, S., Miller-Messana, M.A., Shoemaker, D., Garst, J. and Schwab, G. (2000) Randomized, dose-escalation study of SD/ 01 compared with daily filgrastim in patients receiving chemotherapy. J. Clin. Oncol., 18, 2522-2528.

Inazawa, T. (2014) A case of platelet and white blood cell reduction associated with pioglitazone and fenofibrate. Diabetol. Int., 5, 202-205. crossref(new window)

Thoolen, B., Maronpot, R.R., Harada, T., Nyska, A., Rousseaux, C., Nolte, T., Malarkey, D.E., Kaufmann, W., Kuttler, K., Deschl, U., Nakae, D., Gregson, R., Vinlove, M.P., Brix, A.E., Singh, B., Belpoggi, F. and Ward, J.M. (2010) Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary system. Toxicol. Pathol., 38, 5S-81S. crossref(new window)

Welte, K. (2014) G-CSF: filgrastim, lenograstim and biological similars. Expert Opin. Biol. Ther., 14, 983-993. crossref(new window)

Akizuki, S., Mizorogi, F., Inoue, T., Sudo, K. and Ohnishi, A. (2000) Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects. Bone Marrow Transplant., 26, 939-946. crossref(new window)

Stewart, C.A. (1974) Leucocyte alkaline phosphatase in myeloid maturation. Pathology, 6, 287-293. crossref(new window)

Izumi, M., Ishikawa, J., Takeshita, A. and Maekawa, M. (2005) Increased serum alkaline phosphatase activity originating from neutrophilic leukocytes. Clin. Chem., 51, 1751-1752. crossref(new window)

Frazier, K.S., Seely, J.C., Hard, G.C., Betton, G., Burnett, R., Nakatsuji, S., Nishikawa, A., Durchfeld-Meyer, B. and Bube, A. (2012) Proliferative and nonproliferative lesions of the rat and mouse urinary system. Toxicol. Pathol., 40, 14S-86S. crossref(new window)

Kaufmann, W., Bolon, B., Bradley, A., Butt, M., Czasch, S., Garman, R.H., George, C., Gröters, S., Krinke, G., Little, P., McKay, J., Narama, I., Rao, D., Shibutani, M. and Sills, R. (2012) Proliferative and nonproliferative lesions of the rat and mouse central and peripheral systems. Toxicol. Pathol., 40, 87S-157S. crossref(new window)

Haschek, W.M., Rousseaux, C.G. and Wallig, M.A. (2010) Fundamentals of toxicologic pathology (2nd edition), Academic Press, San Diego, pp. 1-691.

Peter, M. (2012) Background lesions in laboratory animals: a color atlas. Elsevier, New York, pp. 1-256.

Hard, G.C. and Khan, K.N. (2004) A contemporary overview of chronic progressive nephropathy in the laboratory rat, and its significance for human risk assessment. Toxicol. Pathol., 32, 171-180. crossref(new window)